European regulators have approved AstraZeneca PLC’s (LON:AZN) Bydureon BCise once-weekly injection for the treatment of type-2 diabetes.
US authorities had already given the autoinjector pen the green light last October, and the European Commission has now followed suit.
READ: AstraZeneca plots a return to growth as cancer portfolio boosts first-half performance
The new autoinjector features a simpler mixing process, a hidden needle, and a viewing window for users to confirm that they’ve received the medication.
Astra describes Bydureon Bcise as an “improved” version of its predecessor – which goes by the name Bydureon.
Clinical trials showed the device reduces blood sugar and contributes to weight loss.
“Building on the already well-established efficacy and safety profile of once-weekly Bydureon, today's approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise,” said VP late clinical development, Elisabeth Björk.